|
|
Other links at Articles > Allergy and Clinical Immunology |
| 4. |
FDA Safety Changes: Ambien, Primaxin IM/IV, Hepsera
|
|
|
The FDA has approved revisions to the safety labeling for zolpidem tartrate, imipenem-cilastatin intramuscular injection, imipenem-cilastatin intravenous infusion, and adefovir dipivoxil. Medscape Medical News
|
| 5. |
FDA Safety Changes: Levaquin, Nexavar, AndroGel
|
|
|
The FDA has approved revisions to the safety labeling for oral and injectable levofloxacin (Levaquin), sorafenib tosylate tablets (Nexavar), and testosterone 1% gel (AndroGel). Medscape Medical News
|
|
|